Since its approval by the FDA in 2018 and 2020 for cemiplimab and pembrolizumab, respectively, both anti-PD-1 inhibitors have become preferred systemic treatment options for patients with unresectable, recurrent or metastatic cSCC according to the National Comprehensive Cancer Network Guidelines (version 1.2023). Here, PDCD1 is linked to skin squamous cell carcinoma.